A new gene therapy has slowed the progression of Huntingdon's disease by as much as 75%. Known as AMT-130, it is delivered via brain surgery, and a single dose is expected to last someone's whole life. "This result changes everything," said principal investigator Professor Ed Wild. Thirty-year-old Jack May-Davis, who took part in trials, said the results were "astonishing", leaving him "lost for words".